Key result
Renal denervation significantly decreased the renal resistive index by 0.024 at 12 months in patients with resistant hypertension, type 2 diabetes, and elevated baseline renal vascular resistance.
Why the study?
The study was conducted to evaluate the effect of renal denervation on renal vascular resistance and renal function in patients with drug-resistant hypertension and type 2 diabetes mellitus.
Does renal denervation improve renal vascular resistance in patients with resistant hypertension and type 2 diabetes mellitus?
Observational (n=59)
No
Does renal denervation improve renal vascular resistance in patients with resistant hypertension and type 2 diabetes mellitus?
Renal denervation can decrease elevated renal vascular resistance and stabilize kidney function in patients with resistant hypertension and type 2 diabetes mellitus, independent of its blood pressure-lowering effect.
Answers are grounded in this paper and cite their sources.
Renal denervation was associated with lower renal resistive index in this cohort; leaves open clinical benefit pending randomized confirmation.
Objective To assess the effect of renal denervation (RDN) on renal vascular resistance and renal function in patients with drug-resistant hypertension (HTN) and type 2 diabetes mellitus (T2DM). Materials and methods Fifty-nine patients (mean age 60.3 ± 7.9 years, 25 men) with resistant HTN [mean 24-h ambulatory blood pressure (BP) 158.0 ± 16.3/82.5 ± 12.7 mmHg, systolic/diastolic] and T2DM (mean HbA1c 7.5 ± 1.5%) were included in the single-arm prospective study and underwent RDN. Renal resistive index (RRI) derived from ultrasound Doppler; estimated glomerular filtration rate (Chronic Kidney Disease Epidemiology Collaboration formula), office and 24-h ambulatory BP were measured at baseline, 6, and 12 months after RDN to evaluate the respective changes in renal vascular resistance, renal function, and BP during treatment. Results Forty-three patients completed 12 months follow-up. The RRI changed depending on the baseline value. Specifically, the RRI decreased significantly in patients with elevated baseline RRI values ≥ 0.7 { n = 23; −0.024 [95% confidence interval (CI): −0.046, −0.002], p = 0.035} and did not change in those with baseline RRI < 0.7 [ n = 36; 0.024 (95% CI: −0.002, 0.050), p = 0.069]. No significant change was observed in eGFR whereas BP was significantly reduced at 12 months after RDN by −10.9 (95% CI: −16.7, −5.0)/−5.5 (95% CI: −8.7, −2.4) mmHg, systolic/diastolic. No relationship was found between the changes in RRI and BP. Conclusion Our study shows that RDN can decrease elevated renal vascular resistance (RRI > 0.7) and stabilize kidney function in patients with RHTN and T2DM independently of its BP-lowering effect.
No takes yet. Share an insight, caveat, or question.
Manukyan et al. (2022) conducted an observational in Resistant hypertension and type 2 diabetes mellitus (n=59). Renal denervation (RDN) was evaluated on Reduction in renal resistive index (RRI) from baseline to 12 months post-procedure in patients with baseline RRI ≥ 0.7 (95% CI -0.046, -0.002, p=0.035). Renal denervation significantly decreased the renal resistive index by 0.024 at 12 months in patients with resistant hypertension, type 2 diabetes, and elevated baseline renal vascular resistance.
Synapse has enriched 10 related papers. Consider them for comparative context: